Welcome to our dedicated page for Biocryst Pharmaceuticals news (Ticker: BCRX), a resource for investors and traders seeking the latest updates and insights on Biocryst Pharmaceuticals stock.
BioCryst Pharmaceuticals, Inc. develops and commercializes medicines for hereditary angioedema and other rare diseases. Its commercial product ORLADEYO® (berotralstat) is an oral, once-daily plasma kallikrein inhibitor for HAE, and company updates commonly report ORLADEYO revenue, commercial execution, and financial results.
BioCryst news also covers pipeline and portfolio developments, including investigational plasma kallikrein inhibitor navenibart, rare-disease research programs, licensing arrangements, acquisitions, senior R&D leadership changes, investor conference activity, and Nasdaq inducement equity grants tied to new employee hiring.
BioCryst Pharmaceuticals (BCRX) announced the grant of inducement stock options totaling 525,000 shares to two newly-hired employees, including 500,000 shares to CFO Anthony Doyle. The options, granted on April 30, 2020, have an exercise price of $3.91, equal to the stock's closing price on the previous day. Mr. Doyle's options include a vesting schedule tied to his employment status, while the other employee's options vest over four years. These grants comply with NASDAQ Listing Rule 5635(c)(4), aimed at attracting talent to support BioCryst's ongoing development in rare diseases.